23 EzakiB.YamamotoY.MatsumotoH
However, researchers and clinicians have observed its potential in a much broader population, especially in the context of: Visceral adiposity (deep belly fat) Growth hormone deficiency Cognitive aging Cardiometabolic risk reduction Its appeal lies in the ability to elevate IGF-1 (insulin-like growth factor-1) levels while preserving the bodys natural feedback mechanisms
Once you know your window, you can plan around it
Asian Journal of Psychiatry, 6 (1), 29-34
If you want the full picture of the evidence, including where it's strong and where it's still thin, read What Is GHK-Cu
Phase 3 clinical trials for obesity and type 2 diabetes are currently underway in China, while Phase 2 trials for the same indications are ongoing in the United States